Lung CancerNCT06592430
The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns
An observational study of Lung Cancer, run by Shanghai Pulmonary Hospital, Shanghai, China.
Trial summary
The use of smartphone-based WeChat applications offers significant advantages in cancer patient education, rehabilitation monitoring, and postoperative symptom management. Through the WeChat platform, patients can access health education materials, engage in online consultations, and interact with doctors and other… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers and Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
- How many people
- 2,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2024to 1 Oct 2026
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients diagonosed with lung cacner
Who may be able to join
- (1) Lung cancer patients receiving treatment at Shanghai Pulmonary Hospital (2) ECOG performance status of 0-2 (3) No other serious internal medical conditions (such as severe heart failure, hypertensive crisis, diabetic ketoacidosis, severe liver or kidney impairment, etc.) (4) No history of other malignant tumors in the past 5 years, and no detection of other tumor history during follow-up after lung cancer diagnosis (5) Relevant pathological results
Who cannot join
- (1) Patients refused enrollment in this study; （2）Patients refused follow-up.
Trial locations and contacts
No sites are listed yet.
About this study
The use of smartphone-based WeChat applications offers significant advantages in cancer patient education, rehabilitation monitoring, and postoperative symptom management. Through the WeChat platform, patients can access health education materials, engage in online consultations, and interact with doctors and other patients at any time. This ongoing education and psychological support help alleviate patient anxiety and improve their quality of life. This study aims to conduct a prospective observational study in our hospital to explore the impact of WeChat communication on the prognosis of patients with different histological types and stages of lung cancer.
- Conditions
- Lung Cancer
- Being tested
- Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers, Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patients diagnosed with lung cancer use WeChat to communicate with healthcare providersOther
Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers
Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providersOther
Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
| Study group | Role | What they receive |
|---|---|---|
| Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers | Not described Receives: Other: Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers | |
| Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers | Not described Receives: Other: Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival (OS)
It is defined as the time (years) frome enrollment to death of participants due to an cause. In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start1 Oct 2024 (estimated)
- Primary completion1 Oct 2025 (estimated)
- Study completion1 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Shanghai Pulmonary Hospital, Shanghai, ChinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Peng Zhang, Shanghai Pulmonary Hospital, Shanghai, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06592430
- Sponsor's protocol ID
- Wechat-Lung Cancer
- Status last verified
- Sep 2024
- First submitted
- 9 Sep 2024
- Last updated
- 19 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns
- ClinicalTrials.gov ID
- NCT06592430
- Acronym / sponsor ID
- Wechat-Lung Cancer
- Conditions
- Lung Cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaUniversity, hospital or other
- Study start
- 1 Oct 2024 (estimated)
- Primary completion
- 1 Oct 2025 (estimated)
- Study completion
- 1 Oct 2026 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The use of smartphone-based WeChat applications offers significant advantages in cancer patient education, rehabilitation monitoring, and postoperative symptom management. Through the WeChat platform, patients can access health education materials, engage in online consultations, and interact with doctors and other patients at any time. This ongoing education and psychological support help alleviate patient anxiety and improve their quality of life. This study aims to conduct a prospective observational study in our hospital to explore the impact of WeChat communication on the prognosis of patients with different histological types and stages of lung cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers | – | Other: Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers |
| Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers | – | Other: Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients diagonosed with lung cacner
Key inclusion criteria (1 listed)
- (1) Lung cancer patients receiving treatment at Shanghai Pulmonary Hospital (2) ECOG performance status of 0-2 (3) No other serious internal medical conditions (such as severe heart failure, hypertensive crisis, diabetic ketoacidosis, severe liver or kidney impairment, etc.) (4) No history of other malignant tumors in the past 5 years, and no detection of other tumor history during follow-up after lung cancer diagnosis (5) Relevant pathological results
Key exclusion criteria (1 listed)
- (1) Patients refused enrollment in this study; （2）Patients refused follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patients diagnosed with lung cancer use WeChat to communicate with healthcare providersPatients diagnosed with lung cancer use WeChat to communicate with healthcare providers | Other | Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers |
| Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providersPatients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers | Other | Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers |
Primary outcome
Overall survival (OS)
Time frame: 5 years
It is defined as the time (years) frome enrollment to death of participants due to an cause. In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2024.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by Shanghai Pulmonary Hospital, Shanghai, China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Peng Zhang, PhD (021-65115006, zhangpeng1121@tongji.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (OS) (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024; AzTrials last refreshed its copy on 8 Nov 2026.